Having people from different parts of the diabetes care equation talking together at the 3rd Annual Patient-Centered Diabetes Care Meeting is what will move the industry forward, according to Robert A. Gabbay, MD, PhD, chief medical officer and senior vice president at Joslin Diabetes Center and the editor-in-chief of Evidence-Based Diabetes Management journal.
Having people from different parts of the diabetes care equation talking together at the 3rd Annual Patient-Centered Diabetes Care Meeting, co-hosted by The American Journal of Managed Care (AJMC) and Joslin Diabetes Center, is what will move the industry forward, according to Robert A. Gabbay, MD, PhD, chief medical officer and senior vice president at Joslin and the editor-in-chief of AJMC's Evidence-Based Diabetes Management journal.
"The great thing about this conference is the confluence of different backgrounds and interests that are brought together," he said.
The meeting included patients discussing social media and diabetes care, providers outlining innovative models through which they deliver diabetes care, and payers providing their input on the whole spectrum of care.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More